insiderwall
Menu
SuperinvestorInsider
Ideaya Biosciences Inc. IDYA

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397, a

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees145
TickerIDYA

Statistics

Market Cap$2.72B
Revenue (TTM)$218.7M
Net Income-$113.7M
Net Margin-52.0%
EPS$-1.28
P/E-22.54
P/S12.11
P/B2.70
EV/EBITDA-10.47
ROE-14.3%
Dividend Yield
Price$30.93

Data: Twelve Data · Revenue = mcap / P/S